Loading
The VENTANA SP263 assay is an immunohistochemistry stain that measures PD-L1 on tumour cells. Approved in 2017 alongside durvalumab in bladder cancer, it became the companion test in 2021 for adjuvant atezolizumab in resected lung cancer with PD-L1 on at least 1% of tumour cells, and it agrees closely with 22C3, so laboratories often validate it as a single platform.
Approved 1 May 2017 (PMA P160046) alongside durvalumab in urothelial carcinoma as a complementary test, SP263 became a companion diagnostic in 2021 for adjuvant atezolizumab in resected stage II-IIIA non-small-cell lung cancer with PD-L1 on at least 1% of tumour cells (IMpower010). In Europe the CE-IVD version carries claims for pembrolizumab, nivolumab and durvalumab across lung, bladder and head and neck cancers, and SP263 is the assay most often shown to be concordant with 22C3 in harmonisation studies. Laboratories frequently validate SP263 as a single platform for several drugs.
Rabbit monoclonal antibody SP263 on the BenchMark ULTRA stainer, scored as the percentage of tumour cells with membrane staining (tumour-cell score). Connects to PD-L1.
1.VENTANA PD-L1 (SP263) Assay slips into a pocket on PD-L1.
| Region | Year | Indication |
|---|---|---|
| US | 2017 | Complementary PD-L1 assay for durvalumab in urothelial carcinoma |
| US | 2021 | Companion diagnostic for adjuvant atezolizumab in PD-L1 TC ≥1% resected NSCLC |
| EU | 2017 | CE-IVD with claims for several PD-1/PD-L1 antibodies |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"VENTANA PD-L1 SP263 Assay" OR ABSTRACT:"VENTANA PD-L1 SP263 Assay" OR TITLE:"VENTANA PD-L1" OR ABSTRACT:"VENTANA PD-L1" OR TITLE:"SP263" OR ABSTRACT:"SP263") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about VENTANA PD-L1 (SP263) Assay, not a curated reading list.
Shares VENTANA PD-L1 (SP142) Assay, PD-L1 TPS (tumour proportion score), PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer, PD-L1 expression testing (22C3, SP142, SP263) and the tag test.
Shares Companion diagnostics, Histopathology & immunohistochemistry, Roche / Genentech, Triple-negative breast cancer (TNBC) and the tag test.
Shares Companion diagnostics, Roche / Genentech, Non-small-cell lung cancer and the tag test.
Shares Companion diagnostics, Immunohistochemistry (IHC), Histopathology & immunohistochemistry, Roche / Genentech and the tag test.
Shares Companion diagnostics, Non-small-cell lung cancer and the tag test.
Shares Companion diagnostics, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag test.
Shares Companion diagnostics, Triple-negative breast cancer (TNBC) and the tag test.
Shares Companion diagnostics, Triple-negative breast cancer (TNBC) and the tag test.